UBS O'Connor’s Sarepta Therapeutics SRPT Stock Holding History

UBS O'Connor’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-15,000	Closed	-$40.5K	–	600
2024 Q2	$40.5K	Sell	15,000 -20,000	-57%	-$2.57M	﹤0.01%	455
2024 Q1	$318K	Buy	+35,000	New	+$4.29M	0.01%	365
2023 Q4	–	Sell	-10,000	Closed	-$229K	–	595
2023 Q3	$229K	Buy	+10,000	New	+$1.13M	﹤0.01%	445

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS O'Connor's SRPT Position: Q3 2024 in Review

UBS O'Connor sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 2,000 shares — an estimated $276K sold.

UBS O'Connor first reported a position in SRPT in Q1 2018 and held it in 4 quarters. The position peaked at $2.23M in Q4 2023. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

UBS O'Connor reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
UBS O'Connor sold 2,000 Sarepta Therapeutics shares in Q3 2024, an estimated $276K.
UBS O'Connor first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 4 quarters.
UBS O'Connor's Sarepta Therapeutics position peaked at $2.23M in Q4 2023.
457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.